A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care

Conditions

• Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• No Intervention — OTHER
  This is a non-interventional study.

Study Details

The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and activity is impacted and learn about their CIDP signs and symptoms. Other aims are to collect information on any medical problems or side effects during the treatment with HyQvia, learn how effective treatment of CIDP with HyQvia is and understand details on the use of HyQvia in standard clinical routine as well on the need for healthcare intervention (such as emergency room visits or hospital visits or stays). During the study, data will be collected from medical records already available, interviews with participants at study start and study completion and via questionnaires completed by participants. Participants will be treated as per the doctor's or the clinic's routine.

Key Dates

Start date

Apr 29, 2025

Status verified

Nov 2025

Primary completion

Aug 17, 2027

Completion

Aug 17, 2027

Study Design

Enrollment

30 participants (estimated)

Arms

• Arm: Cohort A: New Users of HyQvia
  Participants with CIDP who intend to switch to HyQvia within 6 weeks after enrollment will be interviewed and data from medical records will be reviewed for 12 months.
• Arm: Cohort B: Current Users of HyQvia
  Participants with CIDP who switched to HyQvia within 6 weeks prior to enrollment will be interviewed and data from medical records will be reviewed for 12 months.

Primary Outcome Measure

Treatment Preference for CIDP Therapy as Measured by Novel Treatment Preference Questionnaires [ Time Frame: Baseline up to 12 months (HyQvia or study discontinuation) ]

Central Contacts

• Takeda Contact
  +1-877-825-3327
  [email protected]

Locations (9)

Find similar trials in Rancho Mirage, CA

Related Studies

• A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  PHASE3 · Recruiting · Takeda · Scottsdale, Arizona
• A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  PHASE2 · Recruiting · Takeda · La Jolla, California